Effects of selective cyclooxygenase‐2 inhibitor robenacoxib on primary cells derived from feline injection‐site sarcoma
Journal of Cellular and Molecular Medicine · 2023
DOI: 10.1111/jcmm.17717 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von Chen-Hui Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine, Graduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Sarcoma, Soft Tissue Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Taiwan University.
Abstract (Originalsprache)
Feline injection‐site sarcomas (FISSs) are highly invasive malignant mesenchymal neoplasms that arise from injection sites in cats. Although the tumorigenesis of FISSs is still uncertain, there is a consensus that FISS is associated with chronic inflammation caused by irritation of injection‐related trauma and foreign chemical substances. Chronic inflammation can provide a proper microenvironment for tumour development, which has been known as one of the risk factors of tumorigenesis in many tumours. To investigate the tumorigenesis of FISS and screen for its potential therapeutic targets, cyclooxygenase‐2 (COX‐2), an inflammation‐enhancing enzyme, was selected as a target for this study. In vitro experiments using FISS‐ and normal tissue‐derived primary cells and robenacoxib, a highly selective COX‐2 inhibitor, were performed. The results demonstrated that expression of COX‐2 could be detected in formalin‐fixed and paraffin‐embedded FISS tissues and FISS‐derived primary cells. Cell viability, migration and colony formation of FISS‐derived primary cells were inhibited, and cell apoptosis was enhanced by robenacoxib in a dose‐dependent manner. However, susceptibility to robenacoxib varied in different lines of FISS primary cells and was not completely correlated with COX‐2 expression. Our results suggest that COX‐2 inhibitors could be potential adjuvant therapeutics against FISSs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Veterinary Medicine, Graduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan.
- Institute of Biotechnology, National Taiwan University, Taipei, Taiwan.
- School of Veterinary Medicine, Institute of Veterinary Clinical Science, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Yen-Chen Chang
Förderung
- National Taiwan University
Zitieren
APA
Lu, C. H., Yu, S. H., Wu, C. H., Yeh, J. L., Chang, H. W., Jeng, C. R., & Chang, Y. C. (2023). Effects of selective cyclooxygenase‐2 inhibitor robenacoxib on primary cells derived from feline injection‐site sarcoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17717
Vancouver
Lu CH, Yu SH, Wu CH, Yeh JL, Chang HW, Jeng CR, et al. Effects of selective cyclooxygenase‐2 inhibitor robenacoxib on primary cells derived from feline injection‐site sarcoma. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17717
BibTeX
@article{Lu2023,
author = {Lu, Chen-Hui and Yu, Shu-Han and Wu, Ching-Ho and Yeh, Jason Lih-Seng and Chang, Hui-Wen and Jeng, Chian-Ren and Chang, Yen-Chen},
title = {Effects of selective cyclooxygenase‐2 inhibitor robenacoxib on primary cells derived from feline injection‐site sarcoma},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
doi = {10.1111/jcmm.17717}
}
EUVIMED